Gene can worsen outcome of cancer, accelerating the metabolism of drugs ;
Some patients with breast cancer, lung cancer and leukemia appear to be poor after treatment due to the effects of a particular gene, a new study finds.
The gene, called CYP3A7, is normally only active in childhood, but in some people who are still on into adulthood, and over-active metabolism.
Adults with active copies of the gene produce enzymes that break down hormones and about half of all drugs in clinical use -. potentially reducing the effectiveness of some cancer treatments
Scientists at the Institute of Cancer Research, London, found that 7-8 percent of about 2,500 cancer patients analyzed had a cluster of variations of a single letter in the DNA code causing CYP3A7 to be active in adults.
If the results are confirmed in other studies, could help suggest ways to improve the optimization of cancer treatments for patients with this version of the CYP3A7 gene.
The study, published today (Thursday) in the journal Cancer Research was funded by organizations, including breast cancer now, Bloodwise and Cancer Research UK.
Researchers set out to determine whether the set of genetic variants – that had been previously associated with both levels of the female sex hormone estrogen and the risk of developing breast cancer – was also associated with greater risk of poor cancer outcomes.
was carried out a series of tests on samples of 1,008 women with breast cancer treated at the Royal Marsden NHS Foundation Trust, 347 patients lung cancer and chronic lymphocytic leukemia 1,128.
Scientists found that 7-8 percent of patients in each group – breast cancer, lung cancer and leukemia – led to a genetic “tag” one specific point in their cells suggest they had the version of the CYP3A7 gene was still active in adulthood.
They found that in the three groups of cancer patients, the label is associated with a poor prognosis, possibly due to an effect on the way these patients therapeutic cancer drugs break down.
Among patients with breast cancer , the label was associated with an increased risk of 74 percent of dying from breast cancer. Among the lung cancer patients , which was associated with a 43 percent increased risk of death from any cause, and among patients with leukemia, was associated with a 62 percent increased risk of disease progression .
The study suggests that in the future, changing the types or doses of chemotherapy may improve outcomes in carriers of the gene variant for activation of CYP3A7, called CYP3A7 * 1C standard.
study co-leader Dr. Fletcher Olivia, group leader at the Research Center breast cancer now at the Institute of Cancer Research, London, said:
“Our study shows that some patients with breast, lung and leukemia cancer carry a genetic variant that increases their ability to break down hormones. – And drugs have potentially shown that patients with variant tend to have worse outcomes that those who have, and one possibility is that they are eliminating chemotherapy drugs body too efficient.
“We will need more studies to determine whether the genetic variant is exerting its effect by interfering with treatment, and if so, exactly how it is affecting treatment. Our research has no immediate impact on clinical practice, but in the longer term, doctors may be able to take into account the presence of this – and other -. genetic variants in treatment planning in order to ensure that all patients have the treatment that is best for them “
Professor Paul Workman, chief executive of the Institute of Cancer Research, London, said:
“Initially, research on cancer genetics dealt primarily with the establishment of the effects on the risk of developing cancer, but is now also increasingly focus on finding ways to genetic background of a patient can affect the response to treatment.
“This interesting study suggests that genetic effects on the metabolism of a person, and how drugs are processed, could have an impact on the result after being diagnosed with cancer. In the future, it is likely that evidence genetic a much more fundamental part of treatment planning for cancer will be formed, so that genetic variants of this type can be taken into account in choosing the most effective therapy. “
Dr. Richard Berks, Senior Communications Officer Breast Cancer Research Now, he said:
“It is crucial that people with other types of breast cancer and receive the most appropriate treatment, tailored to your specific needs.
“This work could help identify cases where certain drugs will not be effective for individual patients, saving the unnecessary treatment person with a drug and opening the door to an alternative that may be more beneficial for them.
“Research on how to use existing drugs smarter will be critical as we move towards a world of truly personalized medicine, in which people no longer lose their lives breast cancer . ”
This article was originally published on medicalxpress, Read the original article
Posted in: Cancer